Enhanced Photoresponse of Inorganic Cesium Lead Halide Perovskite for Ultrasensitive Photodetector

We report on a simple way to enhance the photoresponse and efficiency of inorganic cesium lead halide (CsPbIBr2) perovskite for use as a light-absorbing layer in photodetectors integrated with a mechanoluminescent (ML) or triboluminescence (TL) materials for pressure sensing applications. Herein, we proposed to integrate a thermal and moisture stable inorganic cesium lead halide-based CsPbIBr2 perovskite with the TL materials to develop a novel pressure sensor for real-time and in-situ structural health monitoring (SHM) of aerospace vehicles’ fuselage, automobiles and structures. However, the inorganic CsPbIBr2 perovskite layer fabricated using a one-step spin-coating method is usually composed of small grain size with a large number of grain boundaries and compositional defects. Therefore, we employed a metal doping approach to enhance the CsPbIBr2 perovskite film quality. By introducing a small amount of silver iodide (AgI), the photoresponse, responsivity, and response time of the detector were enhanced. This work offers a promising approach for developing an integrated ML pressure sensor with high-quality polycrystalline perovskite for SHM

Core outcome set for surgical trials in gastric cancer (GASTROS study): international patient and healthcare professional consensus

Background: Surgery is the primary treatment that can offer potential cure for gastric cancer, but is associated with significant risks. Identifying optimal surgical approaches should be based on comparing outcomes from well designed trials. Currently, trials report different outcomes, making synthesis of evidence difficult. To address this, the aim of this study was to develop a core outcome set (COS)-a standardized group of outcomes important to key international stakeholders-that should be reported by future trials in this field.Methods: Stage 1 of the study involved identifying potentially important outcomes from previous trials and a series of patient interviews. Stage 2 involved patients and healthcare professionals prioritizing outcomes using a multilanguage international Delphi survey that informed an international consensus meeting at which the COS was finalized.Results: Some 498 outcomes were identified from previously reported trials and patient interviews, and rationalized into 56 items presented in the Delphi survey. A total of 952 patients, surgeons, and nurses enrolled in round 1 of the survey, and 662 (70 per cent) completed round 2. Following the consensus meeting, eight outcomes were included in the COS: disease-free survival, disease-specific survival, surgery-related death, recurrence, completeness of tumour removal, overall quality of life, nutritional effects, and 'serious' adverse events.Conclusion: A COS for surgical trials in gastric cancer has been developed with international patients and healthcare professionals. This is a minimum set of outcomes that is recommended to be used in all future trials in this field to improve trial design and synthesis of evidence